Freitag, 22. Januar 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC

JOURNAL ONKOLOGIE – STUDIE

HyperTET Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin

Rekrutierend

NCT-Nummer:
NCT02359474

Studienbeginn:
Januar 2015

Letztes Update:
15.07.2019

Wirkstoff:
Trabectedin

Indikation (Clinical Trials):
Sarcoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Ludwig-Maximilians - University of Munich, Ludwig-Maximilians - University of Munich

Collaborator:
-

Studienleiter

Rolf Issels, MD
Principal Investigator
Ludwig-Maximilians - University of Munich

Kontakt

Studienlocations (3 von 5)

Ludwig-Maximilians University of Munich, Klinikum Großhadern
81377 Munich
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Gesa Schuebbe
Phone: 0049894400
Phone (ext.): 74768
E-Mail: sarkum@med.uni-muenchen.de
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

This trial compares trabectedin alone to trabectedin in combination with regional hyperthermia in patients with high-risk soft tissue sarcoma. The study is designed to demonstrate a significant benefit for sarcoma-therapy by adding regional hyperthermia.
 

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Age > 18 years

- Histologically confirmed STS (primary or recurrent), except: Ewing sarcoma, osteosarcoma, skeletal chondrosarcoma (extraskeletal chondrosacomas are included), GIST, dermatofibrosarcoma protuberans, malignant mesothelioma, rhabdomyosarcoma

- Patients after failure of first-line chemotherapy (anthracyclines with/without ifosfamide) with or without RHT

- Progressive or recurrent tumor which is unresectable or only resectable with adverse functional outcome

- After macroscopic incomplete resection or marginal resection (tumor-free margins < 1 cm)

- Prior chemotherapy, including anthracyclines with/without ifosfamide (with or without RHT) or patients who cannot be given these medicines

- At least one tumor manifestation which is eligible for hyperthermia

- Performance status (ECOG) 0,1 or 2

- More than 3 weeks from last treatment

- Neutrophil count ≥ 1,5 G/l, hemoglobin ≥ 9 g/dl, platelets ≥ 100 G/l

- Albumin ≥ 25 g/l, total bilirubin ≤ 1 x ULN, ALT/AST ≤ 2.5 x ULN, AP ≤ 2.5 x ULN, Cockroft and Gault's calculated creatinine clearance ≥ 30 ml/min, CPK ≤ 2.5 x ULN

- Patients with the ability to follow study instructions and likely to attend and complete all required visits

- Written informed consent of the subject

Exclusion Criteria:

- Uncontrolled infection (e.g. active viral hepatitis)

- Unstable cardiac status

- Peripheral neuropathy > grade 2

- Known or persistent abuse of medications, drugs or alcohol

- Other malignancy during the last 5 years (exclusion of basal cell carcinoma or adequately treated cervical carcinoma in situ)

- Prior therapy with Tr or known history of hypersensitivity to drugs with a similar chemical structure

- Pregnancy or breast-feeding

- Females of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration

- Uncontrolled CNS-metastases

- Medical or technical impossibility for hyperthermia to heat the major target lesion

Studien-Rationale

Primary outcome:

1. Progression-free Survival (PFS) (Time Frame - planned after 46 events after start of recruitment which are expected to occur after 27 month)



Secondary outcome:

1. Radiological response according to RECIST (Time Frame - planned after 46 events after start of recruitment which are expected to occur after 27 month)

2. Overall Survival (OS) (Time Frame - planned after 46 events after start of recruitment which are expected to occur after 27 month)

3. Treatment related toxicity (hematological, renal, hepatic, others) (Time Frame - planned after 46 events after start of recruitment which are expected to occur after 27 month)

Studien-Arme

  • Experimental: Trabectedin with regional hyperthermia
    Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease. Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs).
  • Active Comparator: Trabectedin
    Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.

Geprüfte Regime

  • Trabectedin (Yondelis)
  • DNA double-strand breaks:
    The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and "danger signals" are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018).

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie